Ruga has fully uncloaked today and rebrands as Aravive Biologics as it also moves its ops to Houston, Texas, and out of the Bay Area.

Motif Bio has put together a financing package to give it the money to wrap up a Phase III trial of its antibiotic iclaprim.

For the first time, venture capital firms Atlas and Third Rock are coming together in a $48.5 million Series A to create and launch Magenta Therapeutics—a new…

In its Series A announced today Glycomine, an early-stage biotech working on replacement therapies for rare diseases, raised $12 million with help from…

A combination of lower corporate taxes, a sense that deregulation for meds is coming and pricing issues will be dropped, bumped-up stocks and an influx of…

Evotec and the University of Oxford have teamed up to bridge the gap between academic research and industry.

An audible sigh of relief was heard this morning that, at last, the U.S. 2016 election is over. In the end, in what was an oft-controversial, hot-tempered and…

CureVac has raised another $29.5 million to fund the advance of its mRNA pipeline, bringing its total haul up to $360 million.

Venture Capital